Sustained Efficacy Up to 3 Years With Bimekizumab Treatment Across GRAPPA Core Domains in Patients With Psoriatic Arthritis: Long- Term Results From Two Phase 3 Trials

Bimzelx (bimekizumab-bkzx) - UCB

https://static1.squarespace.com/static/6642bbced8b22f3bcd7949a5/t/6a05b7ce0e0e4a17617431e0/1778759630269/APL_v29_iS2_Rev4.pdf

Dr Ken Cai1; Joseph F. Merola2; Laura C. Coates3; Atul Deodhar4; Alice Gottlieb5; Enrique R. Soriano6; Barbara Ink7; Rajan Bajracharya7; Jason Coarse8; Philip J. Mease9

May 26, 2026